Immune complex-based vaccine for pig protection against parvovirus

被引:9
作者
Roic, B
Cajavec, S
Ergotic, N
Lipej, Z
Madic, J
Lojkic, M
Pokric, B
机构
[1] Rudjer Boskovic Inst, HR-10002 Zagreb, Croatia
[2] Fac Vet Med, HR-10000 Zagreb, Croatia
[3] Veterina Ltd, HR-10436 Rakov Potok, Croatia
[4] Croatian Vet Inst, HR-10000 Zagreb, Croatia
来源
JOURNAL OF VETERINARY MEDICINE SERIES B-INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH | 2006年 / 53卷 / 01期
关键词
D O I
10.1111/j.1439-0450.2006.00907.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The insoluble immune complexes (ICs) were prepared under the conditions of double immunodiffusion in gel, using the suspension of the ultrasound treated PK-15 cell-line infected with porcine parvovirus (PPV) containing both viral particles and viral proteins, as well as pig or rabbit anti-PPV polyclonal immune sera. The immunodiffusion performed in an agarose gel allows only viral subunits with a molecular mass equal to or less than 1000 kDa, rather than the viral particles, to diffuse through the gel and reach the point where the immunoprecipitate is to be formed. The immunoprecipitation under the conditions of the diffusion ensures the optimal, i.e. equimolar ratio of both immunoprecipitating components, antibody/antigen in the IC. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the Western blot analyses showed the ICs were composed of two proteins, a protein in which molecular mass corresponded to the VP2 of the PPV and a protein with a molecular mass of the IgG. This suggests that the ICs are mainly composed of the VP2 antigen and IgG class antibodies. The potency of the IC-vaccines prepared in the form of a water-in-oil-in-water emulsion was compared with that of a commercially available, inactivated oil vaccine. The vaccination of gilts, 6 weeks before mating, with the IC containing allogeneic pig antibodies, resulted in the development of high and long-lasting anti-PPV antibody titres, similar to those generated by the licenced vaccine (P > 0.01). The content of the virus material administered by the IC was twice lower than that in the licenced vaccine. Neither systemic nor local reactions were observed in the gilts during the period of the trial with the IC vaccine. The number of viable piglets per litter varied between 9 and 12 and no signs of the PPV infection were detected. Rabbits were used as one of the alternative laboratory animal models accepted for the testing of the vaccine against the PPV. The rabbit humoral immune response generated by the IC containing the allogeneic antibodies were higher than that generated by the ICs containing the xenogeneic pig antibodies. It was similar to that generated by two-times higher content of the virus material administered by a commercially available vaccine. The IC-based vaccines belong to non-replicating, subunit vaccines, which are both ecologically convenient and the safest vaccines of all.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 31 条
  • [1] BACHMANN PA, 1972, P SOC EXP BIOL MED, V140, P1369, DOI 10.3181/00379727-140-36676
  • [2] IMMUNOCHEMICAL ISOLATION OF VACCINIA-VIRUS ANTIGENS
    BIRKBECK, TH
    STEPHEN, J
    [J]. IMMUNOCHEMISTRY, 1971, 8 (11): : 1029 - &
  • [3] CAJAVEC S, 1994, PERIOD BIOL, V98, P21
  • [4] Casal JI, 1999, BIOTECHNOL APPL BIOC, V29, P141
  • [5] Corley MM, 2002, AVIAN DIS, V46, P803, DOI 10.1637/0005-2086(2002)046[0803:EOTIRA]2.0.CO
  • [6] 2
  • [7] STANDARDIZED HEMAGGLUTINATION INHIBITION TEST FOR PORCINE PARVOVIRUS ANTIBODY
    JOO, HS
    DONALDSONWOOD, CR
    [J]. AUSTRALIAN VETERINARY JOURNAL, 1976, 52 (09) : 422 - 424
  • [8] ANTIBODY-RESPONSES OF GUINEA-PIGS, RABBITS AND PIGS TO INACTIVATED PORCINE PARVOVIRUS VACCINES
    JOO, HS
    MOLITOR, TW
    LEMAN, AD
    [J]. VETERINARY MICROBIOLOGY, 1984, 9 (01) : 27 - 33
  • [9] Mapping the antigenic structure of porcine parvovirus at the level of peptides
    Kamstrup, S
    Langeveld, J
    Botner, A
    Nielsen, J
    Schaaper, WMM
    Boshuizen, RS
    Casal, JI
    Hojrup, P
    Vela, C
    Meloen, R
    Dalsgaard, K
    [J]. VIRUS RESEARCH, 1998, 53 (02) : 163 - 173
  • [10] Lo-Man R, 1998, EUR J IMMUNOL, V28, P1401, DOI 10.1002/(SICI)1521-4141(199804)28:04<1401::AID-IMMU1401>3.0.CO